New offerings allow PharmaCielo to respond to market demand with expanded product range Extracts derived from proprietary cultivars and produced internally at 30,000+ sq. ft. processing and extraction facility Independent analytical verification of unique medicinal profile and high quality Current inventories support immediate new product
TORONTO and RIONEGRO, Colombia (September 22, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is very pleased to announce that the Colombian Intersectoral Commission for Strategic
Not for distribution to United States newswire services or for dissemination in the United States TORONTO, Ontario (November 2, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF) is pleased to announce that Marc Lustig, the highly successful cannabis industry leader with expertise in
Including Initial Shipment, PharmaCielo will deliver total 1,000 kg of product to Customer – with revenue and cash flow reflected in 2020; interim 2021 sales agreement reached for continued Q1 volume and revenue. Relationship adds U.K. and additional E.U. exposure to PharmaCielo’s current commercial relationships
TORONTO, Ontario (November 23, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF) is pleased to announce the closing of its previously announced private placement of units ("Units") of the Company for gross proceeds of $10.0 million. “The closing of this offering further strengthens the Company’s balance sheet
Designation brings PharmaCielo a step closer to EU-GMP compliance; supports continued expansion of medicinal-grade extract exports GACP certification is based on WHO guidelines for quality assurance and control of herbal medicines TORONTO, Canada and RIONEGRO, Colombia (November 25, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the
December 18, 2020 Fellow shareholders, First, I would like to thank you for your trust and support of the Company and its management and employees. 2020 has been anything but a normal year in terms of the challenges we all faced as individuals, as a
December 20, 2020 By Dana Rohrabacher, former U.S. Congressman and PharmaCielo Advisor Here at home-base USA and throughout the world, major changes in the status of cannabis can be expected in the year ahead. After decades of senseless debate and destructive enforcement, there is now
Alliance with AssuredTrans, Inc. will enable PharmaCielo to provide up-front independent laboratory analysis and insurance of its recently expanded product portfolio to potential customers in the U.S., beginning in 2021 Former congressman notes alliance enables S. customers to have confidence in the purity and quality
Loan of COP$8.5 billion (approximately CDN$3.0 million1) has an 84-month term, 10.14% coupon and revolving component with no equity dilution This loan together with the proceeds of the recent CDN$10mm equity financing put the company in a well-capitalized position to execute on its growing sales
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.